Table 2.

Absolute number of white blood cells (WBC), lymphocytes, CD20, CD3, CD4 and CD8 before the first (T0) and 21 days after the second (T1) vaccine dose in multiple sclerosis subjects under different disease modifying therapies (DMTs). Mann-Whitney two-tailed was performed and a p<0.05 was considered statistically significant.

	DMTs	T0	T1	p-value
WBC (cells/μL)	Interferon β 1a	6162	6169	0.94
	Dimethyl fumarate	6487	5543	0.07
	Teriflunomide	7268	8267	0.35
	Natalizumab	8981	8557	0.79
	Glatiramer acetate	8250	7872	0.99
	Cladribine	5794	5992	0.92
	Fingolimod	5565	5390	0.56
	Ocrelizumab	6808	6142	0.17
Lymphocytes (cells/mm3)	Interferon β 1a	1979	2002	0.84
	Dimethyl fumarate	1284	1322	0.75
	Teriflunomide	1809	2359	0.20
	Natalizumab	3590	3418	0.66
	Glatiramer acetate	2389	2214	0.54
	Cladribine	1135	1203	0.72
	Fingolimod	809	828	0.82
	Ocrelizumab	1594	1648	0.94
CD20 (cells/mL)	Interferon β 1a	233	273	0.74
	Dimethyl fumarate	130	129	0.77
	Teriflunomide	188	225	0.63
	Natalizumab	638	623	0.88
	Glatiramer acetate	154	167	0.65
	Cladribine	105	133	0.58
	Fingolimod	30	51	0.26
	Ocrelizumab	10	32	0.07
CD3 (cells/mL)	Interferon β 1a	1441	1488	0.97
	Dimethyl fumarate	871	853	0.93
	Teriflunomide	1331	1814	0.22
	Natalizumab	2333	2319	0.79
	Glatiramer acetate	1795	1741	0.60
	Cladribine	800	828	0.91
	Fingolimod	506	498	0.84
	Ocrelizumab	1320	1382	0.77
CD4 (cells/mL)	Interferon β 1a	957	1009	0.80
	Dimethyl fumarate	628	650	0.85
	Teriflunomide	816	1079	0.06
	Natalizumab	1424	1317	0.45
	Glatiramer acetate	1134	1075	0.99
	Cladribine	451	477	0.85
	Fingolimod	289	277	0.84
	Ocrelizumab	839	891	0.71
CD8 (cells/mL)	Interferon β 1a	202	223	0.81
	Dimethyl fumarate	114	115	0.88
	Teriflunomide	189	272	0.19
	Natalizumab	373	341	0.54
	Glatiramer acetate	273	286	0.49
	Cladribine	124	125	0.85
	Fingolimod	88	77	0.91
	Ocrelizumab	234	254	0.46